2018 中国专家共识:食管癌放疗患者肠内营养-英文版

2018-11-20 中国抗癌协会肿瘤营养与支持治疗专业委员会 Future Oncol. 2018 Nov 20.

接受放射治疗的食管癌患者发生营养不良的风险较高,且可增加放射治疗的副作用。因此对于该类患者进行及时正确的营养治疗非常关键。本文主要针对食管癌放疗患者肠内营养的相关内容提出指导建议,内容涉及营养筛查评估,营养咨询,肠内营养的适应证,疗效评估,营养计划调整以及家庭肠内营养等。

中文标题:

2018 中国专家共识:食管癌放疗患者肠内营养-英文版

英文标题:

Enteral nutrition in esophageal cancer patients treated with radiotherapy: a Chinese expert consensus 2018.

发布日期:

2018-11-20

简要介绍:

接受放射治疗的食管癌患者发生营养不良的风险较高,且可增加放射治疗的副作用。因此对于该类患者进行及时正确的营养治疗非常关键。本文主要针对食管癌放疗患者肠内营养的相关内容提出指导建议,内容涉及营养筛查评估,营养咨询,肠内营养的适应证,疗效评估,营养计划调整以及家庭肠内营养等。 

拓展指南:食管癌相关指南:

相关资料下载:
[AttachmentFileName(sort=100, fileName=2018 中国专家共识:食管癌放疗患者肠内营养-英文版)] GetToolGuiderByIdResponse(projectId=1, id=c0ac01c00166e150, title=2018 中国专家共识:食管癌放疗患者肠内营养-英文版, enTitle=Enteral nutrition in esophageal cancer patients treated with radiotherapy: a Chinese expert consensus 2018., guiderFrom=Future Oncol. 2018 Nov 20., authorId=null, author=, summary=接受放射治疗的食管癌患者发生营养不良的风险较高,且可增加放射治疗的副作用。因此对于该类患者进行及时正确的营养治疗非常关键。本文主要针对食管癌放疗患者肠内营养的相关内容提出指导建议,内容涉及营养筛查评估,营养咨询,肠内营养的适应证,疗效评估,营养计划调整以及家庭肠内营养等。 , cover=, journalId=null, articlesId=null, associationId=1418, associationName=中国抗癌协会肿瘤营养与支持治疗专业委员会, associationIntro=, copyright=0, guiderPublishedTime=Tue Nov 20 00:00:00 CST 2018, originalUrl=, linkOutUrl=, content=<div>接受放射治疗的食管癌患者发生营养不良的风险较高,且可增加放射治疗的副作用。因此对于该类患者进行及时正确的营养治疗非常关键。本文主要针对食管癌放疗患者肠内营养的相关内容提出指导建议,内容涉及营养筛查评估,营养咨询,肠内营养的适应证,疗效评估,营养计划调整以及家庭肠内营养等。 </div> <div><br> </div>拓展指南:<strong>与<font color=red>食管癌</font>相关指南:</strong><br><ul><li><a href="http://www.medsci.cn/guideline/show_article.do?id=40d101c00160031e" title="2018 台湾共识声明:食管癌的营养治疗" target=_blank>2018 台湾共识声明:食管癌的营养治疗</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=2c8aa1c0015235e6" title="食管癌根治术胸部淋巴结清扫中国专家共识(2017版)" target=_blank>食管癌根治术胸部淋巴结清扫中国专家共识(2017版)</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=199401c001a66298" title="2017年UICC/AJCC 第8版肺癌/食管癌TNM分期标准" target=_blank>2017年UICC/AJCC 第8版肺癌/食管癌TNM分期标准</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=857ac1c001288284" title="2016 ESMO临床实践指南:食管癌的诊断,治疗及随访" target=_blank>2016 ESMO临床实践指南:食管癌的诊断,治疗及随访</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=1f3441c0011e3a4d" title="中国早期食管癌筛查及内镜诊治专家共识意见精简版(2014年,北京)" target=_blank>中国早期食管癌筛查及内镜诊治专家共识意见精简版(2014年,北京)</a></li> 更多信息请点击:<a href="http://www.medsci.cn/guideline/list.do?q=%E9%A3%9F%E7%AE%A1%E7%99%8C" target=_blank>有关食管癌更多指南</a></ul>, tagList=[TagDto(tagId=751, tagName=食管癌), TagDto(tagId=83471, tagName=放疗患者), TagDto(tagId=1467, tagName=肠内营养)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=24, categoryName=胸心外科, tenant=100), CategoryDto(categoryId=66, categoryName=营养科, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=8208, appHits=264, showAppHits=0, pcHits=5846, showPcHits=2752, likes=135, shares=9, comments=4, approvalStatus=1, publishedTime=Mon Nov 26 21:18:44 CST 2018, publishedTimeString=2018-11-20, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=qiushida2, createdTime=Mon Nov 26 21:18:44 CST 2018, updatedBy=null, updatedName=null, updatedTime=Wed Jan 03 20:56:48 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=2018 中国专家共识:食管癌放疗患者肠内营养-英文版)])
2018 中国专家共识:食管癌放疗患者肠内营养-英文版
下载请点击:
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=906390, encodeId=cb91906390d2, content=66666, beContent=null, objectType=guider, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e52b5391436, createdName=ms8000001126610887, createdTime=Wed Dec 09 16:10:04 CST 2020, time=2020-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=906389, encodeId=fcac9063893f, content=6666, beContent=null, objectType=guider, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e52b5391436, createdName=ms8000001126610887, createdTime=Wed Dec 09 16:09:54 CST 2020, time=2020-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=353836, encodeId=151135383696, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Wed Nov 28 07:04:42 CST 2018, time=2018-11-28, status=1, ipAttribution=)]
    2020-12-09 ms8000001126610887

    66666

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=906390, encodeId=cb91906390d2, content=66666, beContent=null, objectType=guider, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e52b5391436, createdName=ms8000001126610887, createdTime=Wed Dec 09 16:10:04 CST 2020, time=2020-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=906389, encodeId=fcac9063893f, content=6666, beContent=null, objectType=guider, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e52b5391436, createdName=ms8000001126610887, createdTime=Wed Dec 09 16:09:54 CST 2020, time=2020-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=353836, encodeId=151135383696, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Wed Nov 28 07:04:42 CST 2018, time=2018-11-28, status=1, ipAttribution=)]
    2020-12-09 ms8000001126610887

    6666

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=906390, encodeId=cb91906390d2, content=66666, beContent=null, objectType=guider, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e52b5391436, createdName=ms8000001126610887, createdTime=Wed Dec 09 16:10:04 CST 2020, time=2020-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=906389, encodeId=fcac9063893f, content=6666, beContent=null, objectType=guider, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e52b5391436, createdName=ms8000001126610887, createdTime=Wed Dec 09 16:09:54 CST 2020, time=2020-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=353836, encodeId=151135383696, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Wed Nov 28 07:04:42 CST 2018, time=2018-11-28, status=1, ipAttribution=)]